Immunotherapy in Bellini Duct Carcinoma: A Systematic Review. (PubMed, Oncol Res) - Sep 23, 2026 - "The SUNNIFORECAST randomised phase II trial reported a CDC-specific ORR of 40% with ipilimumab + nivolumab versus 20% with standard of care (n = 9 CDC). ICIs-particularly combination strategies-demonstrate clinically meaningful activity in selected patients with CDC, but evidence is limited by small samples, heterogeneity and high risk of bias. Prospective, biomarker-informed CDC-dedicated trials and coordinated registries are needed."
IO biomarker • Journal • Review • Genito-urinary Cancer • Infectious Disease • Kidney Cancer • Oncology • Pneumonia • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor
|
|
Alejandra Ivars-Rubio; Ana Belén Arroyo; Andrés Nieto-Olivares; Antonio David Lázaro-Sánchez; Belén Fernández-Molina; Edgardo D Carosella; Ginés Luengo-Gil; Javier David Benítez-Fuentes; María José Sánchez de Las Matas Garre; María Nevado-Rodríguez; Marta Zafra-Poves; Pablo Conesa-Zamora; Sofía Wikström-Fernández
|